NOVO NORDISK A S
About NOVO NORDISK A S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $190.3B
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $190.3B
- Dividend yield
- 5.94%
- Shares outstanding
- 4.6B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 30, 1981
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 49% below its 52-week high.
- Pays a dividend yielding about 5.94% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NOVO NORDISK A S.
Write a review
News about NOVO NORDISK A S
News & sentiment via Polygon.io
